191 related articles for article (PubMed ID: 35544729)
1. Negative Ultraselection of Patients With
Randon G; Maddalena G; Germani MM; Pircher CC; Manca P; Bergamo F; Giordano M; Sposetti C; Montagna A; Vetere G; Zambelli L; Rasola C; Boccaccino A; Pagani F; Ambrosini M; Massafra M; Fontanini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
JCO Precis Oncol; 2022 Apr; 6():e2200037. PubMed ID: 35544729
[TBL] [Abstract][Full Text] [Related]
2. Negative Hyperselection of Patients With
Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
[TBL] [Abstract][Full Text] [Related]
3. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract][Full Text] [Related]
4. Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
Wang C; Sandhu J; Fakih M
Oncologist; 2022 Mar; 27(2):104-109. PubMed ID: 35641204
[TBL] [Abstract][Full Text] [Related]
5. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
Cremolini C; Morano F; Moretto R; Berenato R; Tamborini E; Perrone F; Rossini D; Gloghini A; Busico A; Zucchelli G; Baratelli C; Tamburini E; Tampellini M; Sensi E; Fucà G; Volpi C; Milione M; Di Maio M; Fontanini G; De Braud F; Falcone A; Pietrantonio F
Ann Oncol; 2017 Dec; 28(12):3009-3014. PubMed ID: 29045518
[TBL] [Abstract][Full Text] [Related]
6. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
7. EGFR Amplification in Metastatic Colorectal Cancer.
Randon G; Yaeger R; Hechtman JF; Manca P; Fucà G; Walch H; Lee J; Élez E; Seligmann J; Mussolin B; Pagani F; Germani MM; Ambrosini M; Rossini D; Ratti M; Salvà F; Richman SD; Wood H; Nanjangud G; Gloghini A; Milione M; Bardelli A; de Braud F; Morano F; Cremolini C; Pietrantonio F
J Natl Cancer Inst; 2021 Nov; 113(11):1561-1569. PubMed ID: 33825902
[TBL] [Abstract][Full Text] [Related]
8. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
9. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
11. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
Bylsma LC; Gillezeau C; Garawin TA; Kelsh MA; Fryzek JP; Sangaré L; Lowe KA
Cancer Med; 2020 Feb; 9(3):1044-1057. PubMed ID: 31856410
[TBL] [Abstract][Full Text] [Related]
13. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
14. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
17. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
18. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
19. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.
Randon G; Intini R; Cremolini C; Elez E; Overman MJ; Lee J; Manca P; Bergamo F; Pagani F; Antista M; Angerilli V; Ros Montaña FJ; Lavacchi D; Boccaccino A; Fucà G; Brich S; Cattaneo L; Fassan M; Pietrantonio F; Lonardi S
Eur J Cancer; 2022 Jan; 161():90-98. PubMed ID: 34933155
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
